After signing informed consent, the investigator will assess the subject's eligibility for the study. After signing the informed consent form, the investigator will assess the subject's eligibility for the study. The following procedures will be performed during the screening: collection of medical history, recording previous and concomitant therapy, demographic data, recording 12-lead ECG findings on which STEMI diagnosis was based, recording date and time of STEMI symptom development, recording date, time and results of coronary angiography (CAG) at admission to the study site, measurement of blood neutrophil count, vital signs, physical examination including measurement of body weight (if hospital bed is available), blood sampling for hematology, biochemistry, determination of concentration of hsCRP and brain natriuretic peptide (BNP; N-terminal (NT)-pro hormone brain natriuretic peptide (NT-pro-BNP)), for females with retained reproductive potential - pregnancy test (test strips).~The subjects meeting selection criteria will be randomized to one of the three groups (in 1:1:1 ratio) for single subcutaneous administration of RPH-104 80 mg, RPH-104 160 mg or placebo.~Screening, randomization and administration of the study products will be made on the same (first) study day.~Further 4-week (28-day) clinical follow-up and additional 6- and 12-month clinical follow-up period will be performed.~The end of clinical part of the study will be the date of the last visit of the last subject within additional 12-month clinical follow-up.~The maximum number of screened patients will be 146 subjects, 102 subjects will be randomized, 34 subjects per group.
The goal of the study is to evaluate the effect of single administration of RPH-104 at 80 mg and 160 mg on parameters of systemic inflammation and outcomes of the disease in subjects with ST-segment elevation myocardial infarction (STEMI)